The role of the extracellular matrix protein TGFBI in cancer.

Autor: Corona A; Department of Pharmacology and Cancer Biology, Duke University Medical center, USA., Blobe GC; Department of Pharmacology and Cancer Biology, Duke University Medical center, USA; Department of Medicine, Duke University Medical Center, USA. Electronic address: gerard.blobe@duke.edu.
Jazyk: angličtina
Zdroj: Cellular signalling [Cell Signal] 2021 Aug; Vol. 84, pp. 110028. Date of Electronic Publication: 2021 Apr 30.
DOI: 10.1016/j.cellsig.2021.110028
Abstrakt: The secreted extracellular protein, transforming growth factor beta induced (TGFBI or βIGH3), has roles in regulating numerous biological functions, including cell adhesion and bone formation, both during embryonic development and during the pathogenesis of human disease. TGFBI has been most studied in the context of hereditary corneal dystrophies, where mutations in TGFBI result in accumulation of TGFBI in the cornea. In cancer, early studies focused on TGFBI as a tumor suppressor, in part by promoting chemotherapy sensitivity. However, in established tumors, TGFBI largely has a role in promoting tumor progression, with elevated levels correlating to poorer clinical outcomes. As an important regulator of cancer progression, TGFBI expression and function is tightly regulated by numerous mechanisms including epigenetic silencing through promoter methylation and microRNAs. Mechanisms to target TGFBI have potential clinical utility in treating advanced cancers, while assessing TGFBI levels could be a biomarker for chemotherapy resistance and tumor progression.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: